SGLT2 Inhibitor Reduces CV, Renal Events in Type 2 Diabetes

ADA 2019 —Dapagliflozin reduced CV death, hospitalization for HF, and progression of CKD among T2DM patients with a wide distribution of baselines CVD risk in DECLARE-TIMI 58.

Source: ConsultantLive - June 17, 2019 Category: Internal Medicine Authors: Kenneth Bender, PharmD, MA Tags: Cardiovascular Disease Diabetes Diabetes Type 2 Source Type: news